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Abstract
Objective. To test the hypothesis that miR-155 regulates monocyte migratory potential via modulation of
chemokine and chemokine receptor expression in RA, and thereby is associated with disease activity.
Methods. The miR-155 copy-numbers in monocytes from peripheral blood (PB) of healthy (n = 22), RA
(n = 24) and RA SF (n = 11) were assessed by real time-PCR using synthetic miR-155 as a quantitative
standard. To evaluate the functional impact of miR-155, human monocytes were transfected with control
or miR-155 mimic, and the effect on transcript levels, and production of chemokines was evaluated by
Taqman low-density arrays and multiplex assays. A comparative study evaluated constitutive chemokine
receptor expression in miR-155/ and wild-type murine (CD115 + Ly6C + Ly6G) monocytes.
Results. Compared with healthy monocytes, the miR-155 copy-number was higher in RA, peripheral
blood (PB) and SF monocytes (PB P< 0.01, and SF P< 0.0001). The miR-155 copy-number in RA PB
monocytes was higher in ACPA-positive compared with ACPA-negative patients (P = 0.033) and correlated
(95% CI) with DAS28 (ESR), R = 0.728 (0.460, 0.874), and with tender, R = 0.631 (0.306, 0.824) and swollen,
R = 0.503 (0.125, 0.753) joint counts. Enforced-expression of miR-155 in RA monocytes stimulated the
production of CCL3, CCL4, CCL5 and CCL8; upregulated CCR7 expression; and downregulated CCR2.
Conversely, miR155/ monocytes showed downregulated CCR7 and upregulated CCR2 expression.
Conclusion. Given the observed correlations with disease activity, these data provide strong evidence that
miR-155 can contribute to RA pathogenesis by regulating chemokine production and pro-inflammatory che-
mokine receptor expression, thereby promoting inflammatory cell recruitment and retention in the RA synovium.
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Rheumatology key messages
. The copy number of miR-155 in blood monocytes correlates strongly with clinical markers of disease activity.
. miR-155 can contribute to RA pathogenesis by regulating chemokine production and pro-inflammatory chemo-
kine receptor expression.
. Induction of chemokine production and down-regulation of chemokine receptor may contribute to monocyte
retention at inflammation sites in RA.
Introduction
A critical pathological feature of RA is the accumulation of
monocytes/macrophages in the synovial tissue [1], where
they serve as predominant cytokine-producing effector
cells [24]. The recruitment of monocytes from the blood
is an important step in disease progression and is mediated
by locally produced chemokines [1]. An improved
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understanding of the mechanisms regulating the recruit-
ment, migration and retention of these cells in RA could
facilitate development of novel biomarkers and therapeutics.
miRNAs are a recently discovered class of post-tran-
scriptional regulators that induce target mRNA degrad-
ation or translation inhibition [5]. Of particular relevance
in the context of joint inflammation in RA is miR-155. Its
expression is upregulated in RA synovial monocytes/
macrophages and fibroblasts [6, 7]. Its overexpression in
macrophages triggers the production of pro-inflammatory
mediators, including TNF-a [6].
Less is known about the expression and function of
miR-155 in RA peripheral blood (PB) monocytes. PB
monocytes serve as precursors for a proportion of syn-
ovial monocytes/macrophages and conceivably circulate
in a primed state ready for recruitment. Epigenetic regu-
lation of their ability to respond to chemokines might
therefore contribute to pathogenesis. We hypothesized
that blood and synovial monocytes from RA patients ex-
hibit miR-155-dependent chemokine and chemokine re-
ceptor regulation that determines their potential for
recruitment to the joint. This hypothesis was tested by
quantifying the copy-number of miR-155, which then
allowed direct comparison between blood and synovial
monocytes; we then used this knowledge to investigate
the role of miR-155 in the regulation of chemokine and
chemokine receptors expression as measures of mono-
cyte migratory potential.
We report here that compared with healthy blood
CD14+monocytes, CD14+monocytes from RA patients
have a higher copy-number of miR-155, and this was cor-
related with RA disease activity. Furthermore, the miR-155
copy-number was higher again in RA SF CD14+cells.
Functionally, we discovered that miR-155 in RA mono-
cytes is induced more robustly by inflammatory challenge
than control monocytes, and that miR-155 enhanced che-
mokine production and downregulated the expression
of the pro-inflammatory chemokine receptor, CCR2.
Commensurate with this, CCR2 was up regulated in
miR155/ monocytes. These data suggest that an ele-
vated miR-155 copy-number in monocytes contributes to
inflammatory cell recruitment (by increasing local chemo-
kine production) and to the retention of cells in RA joints
by reducing their migratory chemokine receptors.
Materials and methods
Patients and healthy donors
PB samples were obtained from RA patients at Glasgow
Rheumatology clinics and from age- and gender-matched
healthy control (HC) subjects. RA patients met the 2010
ACR/EULAR diagnostic criteria. Demographic, clinical
and laboratory information is detailed in supplementary
Table S1, available at Rheumatology Online. SF samples
were collected from RA patients at various routine outpa-
tient Rheumatology Clinics (Glasgow, UK). Demographic,
clinical and laboratory information is detailed in supple-
mentary Table S2, available at Rheumatology Online.
This study was approved by the West of Scotland
Research Ethics Service and all subjects provided
signed informed consent.
Human cell culture
Monocytes
CD14+monocytes from 50 ml PB from healthy donors
(n = 22) and RA patients (n = 24), and from RA SF (n = 11;
2025 ml collected) were isolated using CD14+ micro-
beads (Miltenyi) and an Auto-MACS separator according
to the manufacturer’s protocol. This resulted in an average
of 10.4 (3.5) and 8.8 (2.5) of PB CD14+ cells per healthy
and RA donor, respectively. We obtained between 6 and
11  106 SF CD14+cells. The purity of monocytes was
evaluated by flow cytometry (supplementary Fig. S1 and
Table S2, available at Rheumatology Online). PB
CD14+monocytes (0.35106 per well of a 24-well plate)
were either transfected with miR-155 (functionally mature
miR-155 mimic), control miR mimic or fluorescent control
mimic (CM) Dy547 to demonstrate transfection efficiency
(at 20 nM; Dharmacon), using the N-TER transfection re-
agent (Sigma), or were left untransfected as a control.
After 48 h, the cells and supernatant were collected. In
some cultures, monocytes from healthy donors were incu-
bated with RA SF (n = 3) and expression of miR-155 quan-
tified. The assessment of chemokine production and
mRNA expression, and chemokine receptor mRNA
expression was tested only in cultures where the trans-
fection efficiency was >60% and showed an increase in
miR-155 expression (supplementary Fig. S2, available at
Rheumatology Online). This occurred in 15 HCs and in 16
RA patients. These are listed in supplementary Table S3.
The details of this subgroup did not differ from the main
sample population (supplementary Table S1, available at
Rheumatology Online) and they were therefore considered
as representative. In addition, PB CD14+ monocytes of
HCs and RA patients were cultured alone (HC n = 22, RA
in remission n = 5, active RA n = 19) or in the presence
of different doses of lipopolysaccharide (LPS) (2 ng/ml;
HC n = 18, RA in remission n = 5, active RA n = 17) or
(10 ng/ml; HC n = 9, RA in remission n = 0, active RA
n = 16) for 24 h to determine the effect of inflammatory
challenge on miR-155 expression.
T cell—macrophage co-cultures
CD4+cells were isolated from HCs (n = 6) using CD4
microbeads (Militenyi) and the memory T cell subpopula-
tion expanded and activated by incubation with IL-15
(25 ng/ml), TNF (25 ng/ml) and IL-6 (100 ng/ml) as
described before [8]. CD14+cells from the same donors
were differentiated to macrophages by incubation with M-
CSF (50 ng/ml). After 6 days T cells were added to mono-
cyte-derived macrophages at a ratio of 8:1 for 24 h as
described, and in situ hybridization for miR-155 in macro-
phages was performed [8].
Mouse monocytes
Bone marrow monocytes were FACS-sorted from wild-
type and miR-155/ mice based on the expression of
CD11b, CD115, Ly6C and lack of Ly6G as described [9].
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Detailed information and the flow cytometry gating strat-
egy are provided in supplementary Fig. S6, available at
Rheumatology Online.
RNA isolation and cDNA synthesis
Total RNA was extracted using miRNeasy mini Kit
(Qiagen). cDNA was transcribed from RNA using
miScript Reverse Transcription Kit (Qiagen) according to
the manufacturer’s instruction.
Quantifying miR-155 copy-number
Known copy numbers of synthetic miR-155 mimic
(Dharmacon) and plasmid with cloned housekeeping
control RNU1A were used as standards. To obtain a
standard curve, these were diluted in serial 10-fold dilu-
tions in nuclease-free water to generate a range of stand-
ards from 1  103 to 1  109 copies. Each of these
standards was used alongside cDNA from the samples
in qPCR (miScript Sybr Green PCR kit; Qiagen) with spe-
cific human miR-155 and RNU1A primers (Qiagen).
Based on the standard curves the copy number of
miR-155 and RNU1A in the samples were calculated
and data were presented as the copy-number of miR-
155 per 1 000 000 copies of RNU1A. In some ex-
periments, the expression of miR-155 is presented as a
relative value: 2Ct where Ct = Cycle threshold for
RNU1A minus Ct for miR-155.
Luminex
The concentration of chemokines and cytokines in
CD14+culture supernatants was quantified by immuno-
fluorescence assay using the Multiplex Kit panel I and II
(Millipore UK) on a Bio-Plex platform (Bio-Rad). The
plates were designed to measure TNF-a, IL-1b, IL-10,
CCL2/MCP-1, CCL3/MIP-1a, CCL4/MIP-1b, CCL5/
RANTES, CCL7/MCP-3, CCL8/MCP-2, CCL13/MCP4,
CCL17/TARC, CCL19/MIP-3b, CCL20/MIP-3a, CCL21/
6CKINE, CCL22/MDC, CXCL1/GRO, CXCL5/ENA-78,
CXCL7/NAP-2, CXCL8/IL-8, CXCL9/MIG, CXCL10/IP-10,
CXCL11/I-TAC, CXCL12/SDF-1, CX3CL1/Fractalkine, lym-
photactin and vascular endothelial growth factor A
(VEGFA).
Taqman low-density arrays for chemokine and chemokine
receptor expression
RNA (550 ng) was reverse-transcribed with High Capacity
RNA-to cDNA Kit (Applied Biosystems) following the
manufacturer’s guidelines. Custom-designed TaqMan
low-density arrays plates containing specific primers and
probes for 14 human chemokines/cytokines (CCL25, 7,
8; CCL22; CXCL1; TNF-a; IL-1b; IL-6; IL-8; IL-10; and
VEGF) or for 16 chemokine receptors (CCR110;
CXCR1, 2, 4; XCR1; CX3CR1; and CMKLR1); as well as
for 17 mouse chemokine receptors (CCR13, CCR510,
CXCR26, CX3CR1 and CXCR1) were used with TaqMan
PCR Master Mix, No AmpErase (ABI Ltd) and were run on
a 7900HT TaqMan reader. Ct values were calculated
using 18S rRNA as an endogenous control, and Ct
values were calculated by comparison with the mean
Ct of control samples (CM or wild-type monocytes).
FISH combining fluorescent immunohistochemistry
In Situ hybridization combined with immunohistochemistry
for CD68 was performed using a lock nucleic acid (LNA)
microRNA in situ hybridization Optimization Kit, LNA 50-
and 30-digoxigenin-labelled scramble (GTGTAACACGTCTA
TACGCCCA) and miR-155specific (TATCACGATTAGCATT
AA) probes (all from Exiqon), as described previously [6].
Statistical analysis
The data were analysed by Graph Pad Prism version 5.0
and Minitab software. Intergroup differences were tested
by t-test or by MannWhitney U test, depending on data
distribution or after analysis of variance or KruskalWallis
tests for multiple groups. Data was expressed as
means (S.D.) or median and interquartile range. Correlation
between variables was tested using the two-tailed Pearson
Correlation Coefficient with 95% CI. A P-value < 0.05 was
considered significant.
Results
MiR-155 copy-number in RA PB monocytes was ele-
vated over normal donors and correlated with disease
activity
We, and others, have shown an increased relative expres-
sion of miR-155 in RA peripheral blood mononuclear cells
(PBMCs) [10], synovial biopsies, synovial fibroblasts and
SF-derived CD14+cells [6, 7]. However, the quantitative
expression of miR-155 in purified blood CD14+monocytes
and its relation to disease activity has not been elucidated.
Therefore, we developed a method to calculate the copy-
numbers of miR-155 transcripts, which provides a more
accurate foundation compared with relative expression
methods for biomarker studies. The copy-numbers of
miR-155 transcripts in purified PB (P< 0.009) and SF
CD14+monocytes (P< 0.0001) of RA patients were signifi-
cantly higher than the CD14+monocytes of HCs (Fig. 1A).
To investigate the relationship between miR-155 in purified
blood monocytes and disease parameters, the miR-155
copy-number in PB CD14+was correlated against a variety
of clinical indices and laboratory biomarkers. The miR-155
copy-number correlated with DAS28 (based on ESR)
[Pearson’s R (95% CI) R = 0.728 (0.460, 0.874), P< 0.001
(Fig. 1B)] and with ESR [R =0.546 (0.183, 0.778), P =0.006
(Fig. 1C)]. The miR-155 copy-number in PB CD14+cells posi-
tively correlated with total joint [R =0.631 (0.306, 0.824),
P< 0.001] and swollen joint [R = 0.503 (0.125, 0.753),
P =0.012] counts (Table 1). Patients in remission showed
comparable levels of miR-155 to HCs (Fig. 1D), while
patients with high disease activity demonstrated the highest
copy-number compared with those with moderate disease
activity (P = 0.018) or remission state (P =0.015) and HCs
(P = 0.0025). There was an increased expression of miR-
155 copy-number in monocytes from patients positive for
ACPA compared with ACPA-negative patients (P = 0.033)
(Fig. 1E). This was associated with a trend for higher
DAS28 in the ACPA-positive group [4.25 (0.93) vs
3.47 (0.98); P = 0.07]. We found no difference in miR-155
copy-number in PB CD14+cells between patients treated
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with conventional DMARDs or biologics (Fig. 1F). There was
no correlation between the miR-155 copy-number in PB
CD14+cells and the patient’s age or disease duration
(Table 1). Together these data suggest that an elevated
miR-155 is present in RA PB monocytes prior to establish-
ment at sites of inflammation. To investigate whether a high
copy number of miR-155 in SF CD14+cells is associated
with the disease activity in these patients, we did a correla-
tion analysis comparing copy number with DAS28 (ESR).
These patients had a moderate DAS28 (ESR) [mean (S.D.)
of 3.8 (0.6)] (supplementary Table S2, available at
Rheumatology Online). This did not correlate significantly
with the miR-155 copy number in SF monocytes (r = 0.431,
P =0.186), suggesting that additional local factors present at
the site of inflammation effected an extremely high expres-
sion of miR-155 in SF cells.
Active RA blood monocytes expressed higher copy-
numbers of miR-155 upon LPS stimulation than healthy
monocytes
Next, we investigated whether RA monocytes express
disproportionately elevated copy-numbers of miR-155
upon inflammatory stimulus. We quantified the copy-
number of miR-155 in monocytes from HC subjects and
RA patients before and after treatment with different
doses of LPS (2 and 10 ng/ml) (Fig. 1G). The miR-155
copy-number was constitutively increased in RA mono-
cytes. The addition of LPS dose-dependently increased
the copy-number of miR-155 in CD14+monocytes, and
this was exacerbated in RA patients (Fig. 1G). Upon stra-
tification of RA patients into RA in remission and active
RA, the constitutive miR-155 expression in RA patients in
remission was similar to that of HC subjects, and
responded to the similarly low-dose LPS found in HC sub-
jects (supplementary Fig. S3, available at Rheumatology
Online). This suggested that RA monocytes were epigen-
etically programmed at the periphery; with blood mono-
cytes from active RA primed to robustly increase miR-155
expression in response to re-stimulation.
RA SF and a direct contact with T cells increased
miR-155 expression
To investigate which soluble and cellular factors upregu-
late miR-155 in monocytes in the RA synovial
FIG. 1 Copy-number of miR-155 in RA monocytes
(A) miR-155 in CD14+ of RA peripheral blood (PB) (n = 24), SF (n = 11) and healthy controls (HCs; n = 22). (B and C)
Correlations between miR-155 and clinical parameters. (D) miR-155 in RA with clinical remission, moderate (MDA) and
high disease activity (HDA). (E) miR-155 in ACPA-positive vs ACPA-negative patients. (F) miR-155 in conventional (c) vs
biological disease-modifying antirheumatic drugs (DMARDs) treated RA. (G) miR-155 in PB CD14+ of HCs (n = 922) and
RA patients (n = 1624) cultured with LPS for 24 h. *HC vs RA (*P4 0.05, **P4 0.005 and ***P4 0.0005);
y
stimulation vs
control conditions (
y
P40.05,
yy
P40.005 and
yyy
P40.0005). Data are presented as median (interquartile range).
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compartment, healthy blood monocytes were cultured
with RA SFs, or monocyte-derived macrophages co-
cultured with autologous activated memory T cells.
Stimulation with SF or contact with activated memory
T cells upregulated miR-155 transcript expression in
these monocytes/macrophages (Fig. 2). These data indi-
cate that the RA synovial environment (mediators or cells)
may be responsible for an additional increase in the
expression of miR-155 in RA SF CD14+as compared
with blood CD14+.
miR-155 increased pro-inflammatory chemokine produc-
tion by monocytes
miR-155 is a master regulator of cytokine production by
human monocytes and macrophages, and its induced
expression mimics pro-inflammatory activation of cells
[6, 7]. Given the differential expression of miR-155 in RA
monocytes from PB and synovial compartments, we
investigated the contribution of miR-155 to epigenetic
regulation of the chemokines and chemokine receptors
that govern migration of monocytes from blood to sites
of inflammation. To examine the role of miR-155 in che-
mokine production in vitro, we replicated the high expres-
sion levels of miR-155 in synovial CD14+ by transfecting
blood CD14+ monocytes of HCs and RA patients with a
functional miR-155 mimic (miR-155m) or CM and
assessed the levels of chemokine production and mRNA
expression by multiplex ELISA (14 chemokines; n = 15
healthy, n = 16 RA) and TaqMan low-density array (22 che-
mokines; n = 8 for both HCs and RA) assays, respectively.
Enforced expression of miR-155 in CD14+ blood mono-
cytes from RA and healthy subjects stimulated the
production of TNF-a (supplementary Fig. S4, available at
Rheumatology Online) consistent with previous observa-
tions [6, 11], but in addition, stimulated the production of
the chemokines CCL3, CCL4, CCL5 and CCL8 in RA and
CCL3 in healthy monocytes compared with controls trans-
fected with CM (Fig. 3). The supernatant concentrations of
CCL2, CCL7, CCL21, CCL22, CXCL1, CXCL5, CXCL7,
CXCL8, CXCL10 and CX3CL1 were low or unchanged,
the latter suggesting that miR-155 did not regulate their
expression (data not shown).
Next, we investigated mRNA transcript levels of CCL3,
CCL4, CCL5, CCL8 and TNF-a. Consistent with protein
expression (Fig. 3), mRNA transcript levels for these che-
mokines were upregulated in both RA and healthy mono-
cytes transfected with miR-155 (supplementary Fig. S5,
available at Rheumatology Online). These data suggest
that miR-155 supports pro-inflammatory chemokine
production.
miR-155 regulated chemokine receptor expression in
monocytes
Monocyte trafficking in response to chemokines into
tissue sites of inflammation is under the control of specific
chemokine receptors [12, 13]. Therefore, we investigated
the impact of miR-155 on the expression of chemokine
receptors by enforced expressing of miR-155 in
CD14+blood monocytes from RA and healthy subjects.
Since chemokine receptors are generally poorly recog-
nized by antibodies, we evaluated their transcriptional
regulation herein. Among the 15 chemokine receptors
tested, miR-155 transfected into RA CD14+blood mono-
cytes stimulated an increase in transcript levels of CCR7
TABLE 1 Correlation of miR-155 copy numbers with a variety of demographic and clinical indices
miR-155 copy no. Age DD ESR CRP TJS SJS
Age 0.239
(0.58, 0.18)
0.260
DD 0.064 0.464
(0.45, 0.34) (0.07, 0.73)
0.766 0.022
ESR 0.546 0.136 0.108
(0.18, 0.77) (0.51, 0.28) (0.49, 0.30)
0.006 0.526 0.615
CRP 0.186 0.169 0.095 0.672
(0.23, 0.54) (0.53, 0.25) (0.48, 0.32) (0.36, 0.84)
0.384 0.429 0.659 0.000
TJS 0.631 0.035 0.127 0.261 0.197
(0.30, 0.82) (0.43, 0.37) (0.29, 0.50) (0.15, 0.60) (0.22, 0.55)
0.001 0.872 0.555 0.218 0.356
SJS 0.503 0.232 0.301 0.565 0.472 0.529
(0.12, 0.75) (0.58, 0.18) (0.62, 0.11) (0.21, 0.78) (0.08, 0.73) (0.16, 0.76)
0.012 0.276 0.152 0.004 0.020
DAS28 0.728 0.193 0.055 0.759 0.600 0.781 0.803
(0.46, 0.87) (0.55, 0.22) (0.44, 0.35) (0.51, 0.88) (0.26, 0.80) (0.55, 0.90) (0.59, 0.93)
0.000 0.366 0.797 0.000 0.002 0.000 0.000
R-values are on top, with 95% CIs below and corresponding P-values in the subsequent line. DD: disease duration; TJS: total
joint score; SJS: swelling joint score.
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FIG. 2 miR-155 was upregulated by RA synovial fluid and co-culture with autologous T cells
(A) Peripheral blood (PB) monocytes were incubated with RA SF (n = 3) for 24 h and expression of miR-155 evaluated by
relative expression to RNU1A. One-way analysis of variance tests, *P 4 0.05. (B) FISH for miR-155 (green) with immu-
nohistochemistry staining for cell nuclei (blue) and macrophage marker (CD68+; red) were performed on macrophageT
cell co-cultures. (ad) Macrophage and T cell co-cultures; (e) T cells alone. (f) Macrophages alone. Orange colour
indicates double-positive CD68 and miR-155 cells.
FIG. 3 In vitro chemokine production in response to enforced expression of miR-155
Spontaneous 48 h in vitro chemokine production by peripheral blood (PB) CD14+ monocytes from (A) RA patients (n = 16)
and (B) healthy controls (n = 15) after transfection with miR-155 mimic (miR-155m) or control mimic (CM), or by
untransfected monocytes (M). Cells were tested in triplicate. Individual values are shown. Comparisons were analysed
using paired t-test and *P 4 0.05 and **P 4 0.005.
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and decreased expression of CCR2 (Fig. 4A). Similarly,
CCR7 was upregulated in healthy monocytes, although
this did not reach statistical significance. In addition,
CCR3 and CXCR4 expression was increased in miR-
155transfected healthy monocytes compared with CM-
transfected cells (Fig. 4B). Other chemokine receptors,
including CCR4, CCR6, CCR8, CCR9 and CCR10 were
low or were below the limit of assay detection (CX3CR1
in RA patients). Pro-inflammatory imprinting of the RA
blood monocytes is likely a contributing factor to the dis-
tinct effect of miR-155 on chemokine receptors in RA as
compared with healthy blood monocytes.
To validate these data in the context of definitive miR-
155 deficiency, we performed a comparative study using
miR-155 genedeficient mice. Bone marrow monocytes
(BMMOs) were sorted based on their expression of
CD11b, Ly6C and CD115 and their lack of Ly6G markers
(supplementary Fig. S6, available at Rheumatology Online).
MiR-155/BMMOs constitutively expressed a signifi-
cantly higher level of CCR2 and showed downregulation
of CCR7 expression (Fig. 4C). The full range of chemokine
receptor expression on miR-155/BMMOs is shown in
supplementary Fig. S7, available at Rheumatology Online).
The contrasting expression of CCR2 and CCR7
between RA blood monocytes with enforced expression
of miR-155 and miR-155deficient mouse monocytes
suggests a potential evolutionarily conserved role for
miR-155 in regulation of the expression of these
receptors.
Discussion
There is intense interest in unravelling those factors that
coordinately regulate cytokine and chemokine production
by macrophages in RA synovitis. Prior studies have impli-
cated miR-155 in the regulation of cytokines in macro-
phages of synovial origin [6, 14]. No studies, however,
have addressed the potential role for miR-155 beyond
this to the regulation of chemokine or chemokine receptor
expression. Moreover, no studies have investigated the
role of miR-155 at the level of absolute copy-number in
monocytes and its clinical significance for disease activity.
We provide herein systematic evidence that miR-155
increased production of the inflammatory chemokines
CCL3, CCL4, CCL5 and CCL8, and regulated CCR2 and
CCR7 chemokine receptor expression in RA PB mono-
cytes. The combination of these phenotypic manifesta-
tions implicates miR-155 in co-ordinating leucocyte
recruitment and retention at the joint spaces in inflamma-
tory disease. This is reflected by a tight positive correla-
tion of miR-155 copy-number in PB monocytes with
disease activity.
Dynamic regulation of chemokine production and che-
mokine receptor expression provides a putative evolutio-
narily conserved molecular mechanism that allows cells to
move from one tissue compartment to another. miR-155
copy-number analysis in monocytes revealed the differen-
tial expression of miR-155 between blood and the
synovial compartment, suggesting an important role for
miR-155 in the regulation of this process. High expression
levels of miR-155 triggered, at transcriptional and protein
levels, increased CCL3 (a ligand for CCR1, CCR3 and
CCR5), CCL4 (a ligand for CCR5), CCL5 (a ligand for
CCR1 and CCR5) and CCL8 (a ligand for CCR2), which
have been asserted as mediating monocyte and T cell
recruitment into inflamed joints [15, 16]. This was asso-
ciated with a reduction in the mRNA expression of inflam-
matory chemokine receptor and marker of classical
monocytes CCR2 [12] in RA CD14+cells. This downregu-
lation of CCR2 on monocytes after transit into the joint
would prevent subsequent egress from the synovial
space. A negative regulatory role for miR-155 in the
expression of this receptor was supported by the pheno-
type of miR-155/ monocytes, which showed upregula-
tion of many pro-inflammatory chemokine receptors,
including CCR2. In contrast to monocytes from RA
patients and mouse BMMOs, CCR2 seemed not to be
affected by miR-155 in monocytes from healthy donors.
We speculate that this could be due to the difference in
the composition of CCR2-expressing monocyte subpopu-
lations in the different experimental groups. RA blood con-
tains an increased percentage of CCR2 inflammatory
FIG. 4 miR-155 regulated chemokine receptor expression
Chemokine receptor mRNA expression in PB CD14+ monocytes from (A) RA patients (n = 8), (B) healthy controls (n = 8)
transfected with miR-155 mimic or control mimics. (C) CCR2 and CCR7 expression in bone marrow monocytes that were
sorted on the basis of CD11b, Ly6C, CD115 and lack of Ly6G expression. The transcript levels of candidate chemokine
receptors were normalized to 18S rRNA (house keeping gene) and then calibrated to control mimictransfected cells or
transcript levels of wild-type mice. All data are presented as mean (S.E.M.), and statistical significances were evaluated by
using the MannWhitney test *P 4 0.05.
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classical monocytes [17], and the Ly6Chigh monocytes
from mouse bone marrow used in this study are also char-
acterized by high CCR2 expression [12]. Thus, miR-155
manipulation might have had an impact only in cells
expressing high levels of CCR2.
Blood monocytes from active RA appear to be
imprinted to disproportionately increase miR-155 expres-
sion upon Toll-like receptor 4 (TLR4) engagement. This is
commensurate with the highest expression levels of miR-
155, which occur in SF CD14+cells situated in a strongly
pro-inflammatory environment (compared with the blood
compartment of healthy subjects and RA patients). Thus,
we suggest that miR-155 induced by endogenous TLR
ligands in the synovial milieu or by contact with other
inflammatory cells [6, 18] exists at high copy-number in
RA SF monocyte/macrophages and mediates chemokine
production that in turn leads to recruitment of blood
monocytes and T cells into the joint space; this then
attenuates the expression of inflammatory chemokine
receptors, retaining these activated cells in the synovium.
In addition, our data indicate that CCR7 is positively regu-
lated by miR-155. CCR7 and its corresponding ligands
have been implicated in lymphoid neogenesis: they are
localized in the lymphocytic infiltration and in dendritic
cells (DCs) in the RA synovium and play a crucial role in
the maturation and homing of DCs to lymphocytic aggre-
gation [19, 20]. Thus, we speculate that some
inflammatory monocytes expressing high levels of miR-
155 and CCR7 can give rise to inflammatory DCs that
are directed to ectopic lymphoid structures in synovium
(Summary Fig. 5).
The mechanism of miR-155 regulation of chemokines
and chemokine receptors is currently unknown. It is
likely that miR-155 impacts the pro-inflammatory signal-
ling pathways implicated in differential chemokine and
chemokine receptor system expression. This could
include the signalling pathways mediated by validated
miR-155 targets SHIP-1 [21] and SOCS-1 [22], which are
inhibitors of myeloid cell activation. In addition, the impact
of miR-155 on monocyte function could be influenced by
the presence of other post-transcriptional regulators of
the inflammatory response, including miR-146 [23] or
lincRNA-Cox2 [24], which can lead to a variation in the
miR-155mediated chemokine/chemokine receptor
expression between healthy subjects and RA patients.
Further studies are required to establish the mechanism
by which miR-155 regulates the balance between chemo-
kine, cytokine and chemokine receptor expression.
In accord with this observation and with other described
pro-inflammatory activities of miR-155, the copy-number
of miR-155 in blood-derived monocytes tightly correlated
with rheumatoid arthritis clinical markers including DAS28,
Total /swollen joint counts and ESR. Future studies will
be required to determine whether miR-155 can serve as a
FIG. 5 Schematic representation of the role of miR-155 in migration and retention of inflammatory cells in synovial tissue
In the RA synovium, Toll-like receptor ligands and a direct contact with activated T cells strongly upregulated miR-155
expression in monocytes/macrophages, and this led to production of pro-inflammatory cytokines and chemokines.
Chemokine activity recruited monocytes and other cells from the peripheral circulation into synovial tissue.
Simultaneously, high expression of local miR-155 leds to downregulation of CCR2 chemokine receptors on synovial
monocytes/macrophages and facilitated their retention in the synovium. Images of the cell were taken from the Protein
Lounge (www.proteinlounge.com).
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useful biomarker of RA disease activity, perhaps included
as part of a poly-factorial algorithm. This may be particu-
larly useful for myeloid targeting therapeutics—for exam-
ple, those targeting the GM-CSF pathway. Several other
studies performed on whole PBMCs or serum have
emphasized the clinical significance of miRNAs in arthritis
as disease-specific biomarkers (serum miR-16 and miR-
223 in early RA, and serum miR-24 and miR-125a-5p in
established RA) or inflammation-specific biomarkers (miR-
146a, miR-132 and miR-16 in PBMCs) [10, 25, 26].
Analysis of the influence of drug therapy on miR-155
copy-number expression revealed no difference between
the conventional DMARDs and the biologics-treated
groups. However, due to the small sample size of the
biologics group in this study, it is recommended that
this be re-evaluated in a larger study appropriately pow-
ered for biomarker discovery.
In summary, our data delineated the complex interac-
tion between chemokine-mediated migration, inflamma-
tory factor stimulation and microRNA epigenetic control
of monocytes in inflammatory joint disease. Our results
collectively imply that miR-155 can act as an important
epigenetic regulator of chemokine and chemokine recep-
tor expression and is a key factor in the clinical manifesta-
tion of RA and its pathogenesis.
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